JP2019523022A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019523022A5 JP2019523022A5 JP2019527769A JP2019527769A JP2019523022A5 JP 2019523022 A5 JP2019523022 A5 JP 2019523022A5 JP 2019527769 A JP2019527769 A JP 2019527769A JP 2019527769 A JP2019527769 A JP 2019527769A JP 2019523022 A5 JP2019523022 A5 JP 2019523022A5
- Authority
- JP
- Japan
- Prior art keywords
- expression
- seq
- hvg161
- results
- cell lines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001850 Nucleic acid sequence Polymers 0.000 description 12
- 210000004027 cells Anatomy 0.000 description 10
- 201000009910 diseases by infectious agent Diseases 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 210000004881 tumor cells Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 102100007290 CD274 Human genes 0.000 description 4
- 101710012053 CD274 Proteins 0.000 description 4
- 210000003501 Vero Cells Anatomy 0.000 description 4
- 230000002457 bidirectional Effects 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 101710037611 BMLF1 Proteins 0.000 description 1
- 101710021191 ICP34.5 Proteins 0.000 description 1
- 102100016020 IFNG Human genes 0.000 description 1
- 101700086956 IFNG Proteins 0.000 description 1
- 101710029649 MDV043 Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
Description
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662369646P | 2016-08-01 | 2016-08-01 | |
US62/369,646 | 2016-08-01 | ||
PCT/US2017/044993 WO2018026872A1 (en) | 2016-08-01 | 2017-08-01 | Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019523022A JP2019523022A (ja) | 2019-08-22 |
JP2019523022A5 true JP2019523022A5 (ja) | 2020-09-10 |
JP7200104B2 JP7200104B2 (ja) | 2023-01-06 |
Family
ID=61074124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019527769A Active JP7200104B2 (ja) | 2016-08-01 | 2017-08-01 | 免疫系刺激分子を発現する腫瘍溶解性単純ヘルペスウイルスベクター |
Country Status (6)
Country | Link |
---|---|
US (1) | US20190169253A1 (ja) |
EP (1) | EP3490583B1 (ja) |
JP (1) | JP7200104B2 (ja) |
AU (1) | AU2017305335B2 (ja) |
CA (1) | CA3032669A1 (ja) |
WO (1) | WO2018026872A1 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017132552A1 (en) | 2016-01-27 | 2017-08-03 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
CA3029426A1 (en) | 2016-06-30 | 2018-01-04 | Oncorus, Inc. | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
CN115820571A (zh) * | 2017-03-09 | 2023-03-21 | 厦门大学 | 一种重组单纯疱疹病毒及其用途 |
SG11202000691XA (en) | 2017-07-26 | 2020-02-27 | Oncorus Inc | Oncolytic viral vectors and uses thereof |
AU2018311079B2 (en) | 2017-08-03 | 2022-06-23 | Amgen Inc. | Interleukin-21 muteins and methods of treatment |
IL293443A (en) | 2017-09-08 | 2022-07-01 | Amgen Inc | kras g12c inhibitors and methods of using them |
US11865081B2 (en) | 2017-12-29 | 2024-01-09 | Virogin Biotech Canada Ltd. | Oncolytic viral delivery of therapeutic polypeptides |
JP2019122373A (ja) | 2018-01-12 | 2019-07-25 | アムジエン・インコーポレーテツド | 抗pd−1抗体及び治療方法 |
TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
JP2022513639A (ja) * | 2018-11-29 | 2022-02-09 | ヴァイロジン バイオテック カナダ リミテッド | 低神経毒性hsvベクター |
TW202039835A (zh) | 2018-12-27 | 2020-11-01 | 美商安進公司 | 凍乾病毒配製物 |
SG11202108449SA (en) | 2019-03-05 | 2021-09-29 | Amgen Inc | Use of oncolytic viruses for the treatment of cancer |
TW202102543A (zh) | 2019-03-29 | 2021-01-16 | 美商安進公司 | 溶瘤病毒在癌症新輔助療法中之用途 |
US20220160852A1 (en) * | 2019-04-05 | 2022-05-26 | The Regents Of The University Of California | Human vaccine compositions and methods for treating leukemia |
CN115960967A (zh) * | 2019-07-29 | 2023-04-14 | 上海复诺健生物科技有限公司 | 表达免疫系统-刺激分子的溶瘤性单纯疱疹病毒载体 |
US20230147832A1 (en) * | 2020-01-22 | 2023-05-11 | City Of Hope | Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer |
CR20220367A (es) * | 2020-02-05 | 2022-08-30 | Novartis Ag | Célula cho que expresa heterodímeros il-15 |
WO2022081776A1 (en) * | 2020-10-13 | 2022-04-21 | Kriya Therapeutics, Inc. | Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer |
US20240042028A1 (en) * | 2020-12-07 | 2024-02-08 | The Johns Hopkins University | Methods of nk cell engineering to enhance tumor targeting |
CN116135972A (zh) * | 2021-11-16 | 2023-05-19 | 中国科学院深圳先进技术研究院 | 基于中国hsv临床分离株的溶瘤病毒及其构建方法和应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6379674B1 (en) * | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
US6713067B2 (en) | 1998-07-31 | 2004-03-30 | Biovex Limited | Herpes viruses for immune modulation |
CA2376939A1 (en) * | 1999-06-08 | 2000-12-14 | Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
EP1252322B2 (en) | 2000-01-21 | 2009-03-04 | BioVex Limited | Herpes virus strains for gene therapy |
US7063851B2 (en) | 2000-04-12 | 2006-06-20 | Biovex Limited | Herpes viruses for immune modulation |
US7939059B2 (en) * | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
DE602004031341D1 (de) * | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
NZ582330A (en) * | 2007-06-27 | 2012-05-25 | Marinepolymer Tech Inc | COMPLEXES OF IL-15 AND IL-15Ra (RECEPTOR ALPHA) AND USES THEREOF |
JP2013527753A (ja) * | 2010-03-23 | 2013-07-04 | イントレキソン コーポレーション | 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用 |
WO2014018423A2 (en) * | 2012-07-25 | 2014-01-30 | The Broad Institute, Inc. | Inducible dna binding proteins and genome perturbation tools and applications thereof |
WO2014047350A1 (en) * | 2012-09-20 | 2014-03-27 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
JP6794255B2 (ja) * | 2013-08-08 | 2020-12-02 | サイチューン ファーマ | 組合せ医薬組成物 |
EP3050095B1 (en) * | 2013-09-27 | 2019-02-13 | Intel Corporation | Dual-sided die packages |
SG11201604781RA (en) | 2013-12-18 | 2016-07-28 | Intrexon Corp | Single chain il-12 nucleic acids, polypeptids, and uses thereof |
-
2017
- 2017-08-01 US US16/322,903 patent/US20190169253A1/en active Pending
- 2017-08-01 EP EP17837576.2A patent/EP3490583B1/en active Active
- 2017-08-01 AU AU2017305335A patent/AU2017305335B2/en active Active
- 2017-08-01 CA CA3032669A patent/CA3032669A1/en active Pending
- 2017-08-01 WO PCT/US2017/044993 patent/WO2018026872A1/en unknown
- 2017-08-01 JP JP2019527769A patent/JP7200104B2/ja active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019523022A5 (ja) | ||
JP7270253B2 (ja) | ナチュラルキラー細胞のエクスビボ拡大及び活性化のための刺激細胞株 | |
EA201892369A1 (ru) | Способы селективной модуляции активности отдельных подтипов клеток | |
Johnson et al. | Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity | |
RU2019144161A (ru) | Последовательности нуклеиновых кислот и аминокислотные последовательности аденовирусов человекообразных обезьян, исключая человека, содержащие их векторы и их применения | |
WO2008140621A3 (en) | Transgenic oncolytic viruses and uses thereof | |
JP2019523008A5 (ja) | ||
JP2017513472A5 (ja) | ||
RU2022103870A (ru) | Модифицированный иммунорегуляторный элемент и изменение иммунитета посредством этого элемента | |
WO2011130749A3 (en) | Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors | |
MX352974B (es) | Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso. | |
JP2019506175A5 (ja) | ||
WO2020163365A3 (en) | Combination gene targets for improved immunotherapy | |
CN108635380A (zh) | 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用 | |
Hope et al. | Striking a balance—cellular and molecular drivers of memory T cell development and responses to chronic stimulation | |
JP2016531927A5 (ja) | ||
JP2016500260A5 (ja) | ||
AU2018273963A1 (en) | Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells | |
SG10201805197VA (en) | Compositions and methods using capsids resistant to hydrolases | |
MX2020007010A (es) | Vectores modificados de orthopoxvirus. | |
JP2018522041A5 (ja) | ||
MX2019008922A (es) | Mutantes de la caja tata y de la caja caat selectivas de tumor. | |
JP2014515258A5 (ja) | ||
Brachtlova et al. | Unleashing the Full Potential of Oncolytic Adenoviruses against Cancer by Applying RNA Interference: The Force Awakens | |
Lundstrom | Latest trends in cancer therapy applying viral vectors |